BiotechTube

OPT-80 + vancomycin

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Clostridium Difficile

Conditions

Clostridium Difficile

Trial Timeline

Jun 23, 2014 → Sep 8, 2016

NCT ID
NCT02179658

About OPT-80 + vancomycin

OPT-80 + vancomycin is a phase 3 stage product being developed by Astellas Pharma for Clostridium Difficile. The current trial status is completed. This product is registered under clinical trial identifier NCT02179658. Target conditions include Clostridium Difficile.

What happened to similar drugs?

8 of 20 similar drugs in Clostridium Difficile were approved

Approved (8) Terminated (4) Active (12)
✅Fidaxomicin + Vancomycin + PlaceboAstellas PharmaApproved
🔄Fidaxomicin oral suspension + Fidaxomicin tablets + Vancomycin oral liquid + Vancomycin capsulesAstellas PharmaPhase 3
✅Fidaxomicin + VancomycinAstellas PharmaApproved
✅Fidaxomicin + VancomycinMerckApproved
🔄fidaxomicin + PlaceboMerckPhase 3
🔄MK-6072 + MK-3415A + Placebo + SOCMerckPhase 3
✅Vancomycin + FidaxomicinMerckApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02179658Phase 3Completed

Competing Products

20 competing products in Clostridium Difficile

See all competitors
ProductCompanyStageHype Score
Metronidazole + Metronidazole-DRF1 + Metronidazole-DRF2Dr. Reddy's LaboratoriesPhase 2
32
Fidaxomicin + Vancomycin + PlaceboAstellas PharmaApproved
35
Fidaxomicin + Treatment for CDI other than fidaxomicin TypeAstellas PharmaPre-clinical
26
Fidaxomicin oral suspension + Fidaxomicin tablets + Vancomycin oral liquid + Vancomycin capsulesAstellas PharmaPhase 3
40
Fidaxomicin + VancomycinAstellas PharmaApproved
43
Fidaxomicin + VancomycinMerckApproved
43
fidaxomicin + PlaceboMerckPhase 3
40
Surotomycin + PlaceboMerckPhase 1
29
CB-183,315 + Placebo + VancomycinMerckPhase 2
35
Surotomycin + PlaceboMerckPhase 1
29
MK-6072 + MK-3415A + Placebo + SOCMerckPhase 3
40
Vancomycin + FidaxomicinMerckApproved
43
FidaxomicinMerckPre-clinical
18
Bezlotoxumab + Standard CDI treatmentMerckPre-clinical
26
MK-3415 + MK-6072 + MK-3415A + Placebo + SOCMerckPhase 3
40
Fidaxomicin + Vancomycin + Matching Placebo to FidaxomicinMerckPhase 3
40
bezlotoxumab + Vancomycin OralMerckApproved
43
Bezlotoxumab + Placebo + Antibacterial drug treatment (ABD)MerckPhase 3
40
Bezlotoxumab Injection [Zinplava]MerckPre-clinical
26
PAR-101/OPT-80 + VancomycinMerckPhase 3
40